Founded in 2017, TLS is the only company developing comprehensive target drugs and neutron technology product portfolio to enable next-generation boron neutron capture therapy (BNCT) as a first-line treatment for patients globally.
The company has made a significant investment in developing a portfolio of new Boron-10 target drugs, with the goal of expanding the application of BNCT to new cancer types and to provide even be...
Founded in 2017, TLS is the only company developing comprehensive target drugs and neutron technology product portfolio to enable next-generation boron neutron capture therapy (BNCT) as a first-line treatment for patients globally.
The company has made a significant investment in developing a portfolio of new Boron-10 target drugs, with the goal of expanding the application of BNCT to new cancer types and to provide even better outcomes for indications historically treated with Boronophenylalanine (BPA), the only target drug currently utilized in BNCT.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.